By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Antipsychotic medicine lurasidone, also marketed as Latuda, is used to treat schizophrenia and bipolar disorder. It is consumed orally. Sleepiness, mobility issues, nausea, and diarrhoea are typical side effects.
Treatment for schizophrenia and other psychotic (mental) illnesses using lurasidone. When treating dementia-related behavioural issues in senior people, this medication should not be utilised.
Bipolar depression can be treated with it either on its own or in combination with other medications (such lithium or valproate). A drug called lurasidone is used to treat bipolar disorder and schizophrenia.
It belongs to the group of drugs called benzisothiazolin. This exercise explains the benefits of lurasidone as a treatment for schizophrenia and bipolar disorder, as well as how it works and when it should not be used.
Lurasidone is offered in tablets with an immediate release in dosages of 20, 40, 60, 80, and 120 mg. After oral use, it is not very soluble in water.
Therefore, regardless of the amount of fat in the meal, it is advised that lurasidone be provided in order to raise its bioavailability to 9 to 19%. The area under the curve doubles, while the Cmax grows by three times.
The peak serum concentration of lurasidone is reached in 1 to 3 hours, and the steady-state concentration is reached in 7 days.
Because the cytochrome P450 enzyme CYP3A4 is principally responsible for lurasidone metabolism, administration of this medication with potent inducers or inhibitors of CYP3A4 should be done with caution.
The Global lurasidone market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) that broadens the use of Latuda (lurasidone HCI) to include the treatment of major depressive episode associated with bipolar I disorder (bipolar depression) in young patients, according to Sunovion Pharmaceuticals Inc.
Additionally, LATUDA has been given U.S. approval for the treatment of schizophrenia in both adults and adolescents as well as for the treatment of bipolar depression in adults who require both monotherapy and adjunctive therapy with lithium or valproate.
